Product Overview
Selank is a synthetic heptapeptide whose sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, was built from tuftsin, a fragment of an immune protein. It was designed at the Institute of Molecular Genetics in Moscow, has a mass close to 752 daltons, and is catalogued by Generic Peptides in two freeze-dried fills, 5 mg and 30 mg. Buyers who search for a nasal anxiety product usually arrive here expecting a pharmacy item, and the first thing worth knowing is that this is a research vial, not the registered nasal preparation sold inside Russia.
The mechanism described in the literature is immunological and neurotrophic rather than sedative. Selank alters cytokine signalling and the balance of T helper cell populations, and it raises BDNF in the rat hippocampus, which is the pathway its cognitive claims rest on. In the Russian clinical work, the effect at low amounts is described as anxiolytic without sedation and without the memory dulling that benzodiazepines produce, and the compound has been compared with those drugs in small studies.
Outside Russia and a few neighbouring countries there is no registration file, no large independent trial and no published pharmacokinetics. That gap does not make the product fake, but it does mean every quantity on this page has to be read as a laboratory convention.
Dosage Protocol
No approved amount exists for people. The figures below are the research pattern printed in vendor notes and in the small Russian papers, followed by the dilution arithmetic that turns a 5 mg or 30 mg fill into a measurable volume.
| Starting point | 250 mcg per intranasal dose, used for one to two weeks in the vendor figures |
| Common research range | 250-500 mcg per intranasal dose, repeated up to three times daily, for around 14 days |
| Upper range | 500-1000 mcg a day in total, run in short blocks; above this the human data stop |
| Route | Intranasal in the Russian schemes, subcutaneous injection in the research variant |
| Two millilitres into the 5 mg vial | Yields 2.5 mg/ml, so a 250 mcg amount sits at the 10 unit mark |
| Five millilitres into the 5 mg vial | Yields 1 mg/ml, so the 10 unit mark delivers 100 mcg |
| 30 mg in 10 ml | 3 mg/ml, so 10 units on the syringe carries roughly 300 mcg |
| 30 mg in 30 ml | 1 mg/ml, which brings the arithmetic back to the diluted 5 mg fill |
| Female | Separate female protocols are absent from the sources checked; none is described |
Reconstitution follows the usual peptide routine: bacteriostatic water down the wall of the vial, a gentle roll rather than a shake, then storage of the solution at 2-8 C for about 28 days. The dry powder holds far longer in the fridge. Because there is no human elimination curve, no dosing interval can be derived from half-life, and the timing conventions in the papers are practical choices rather than pharmacological ones.
Suggested Protocols
No study has run Selank together with another product from this catalogue, so the groupings below are reading aids: the peptides that share its research field, and the compounds that address the same complaint through a completely different mechanism.
What to Expect
- Calm without heaviness. The central observation in the Russian work is an anxiolytic response that does not come with sedation or impaired memory at low amounts.
- Mood effect mostly in animals. Antidepressant-like behaviour has been described in rodent models, and the human record on mood is far thinner.
- Fast neurotrophic signalling. A rapid rise in BDNF has been measured in rat hippocampus, which is the biological story behind the cognitive claims.
- Days, not hours. In the clinical schemes the response is assessed over the opening days of a roughly two week course.
- An immune component. The described action includes shifting the balance of cytokines and T helper populations, which is offered as mechanism rather than reported as a side effect.
- The evidence gap is the honest headline. Preclinical work dominates, Western registration studies do not exist, and animal findings cannot simply be carried across to a person.
Side Effects and Management
This compound has never been run through a large monitored trial, so everything below comes from small studies, vendor notes and user accounts. Management is therefore practical and observational.
Post-Cycle Therapy
Nothing in this vial interacts with the hormonal axis, so a recovery protocol would be an invention and is not written here. Selank leaves testosterone production untouched, has no impact on oestrogen balance and does not disturb fertility or sperm output.
One practical warning closes the section. Selank is not named on the prohibited list, and that omission is not permission: an unlisted research peptide is an absence of data, while a mixed block that also contains Thymosin Alpha-1 or another compound still has to be declared by an athlete under the code's general clauses.
